Atogepant - Allergan

Drug Profile

Atogepant - Allergan

Alternative Names: AGN 241689; MK 8031

Latest Information Update: 12 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck AG
  • Developer Allergan
  • Class Antimigraines; Monoclonal antibodies; Piperidines; Pyridines; Pyrroles; Small molecules; Spiro compounds
  • Mechanism of Action Calcitonin gene-related peptide antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Migraine

Most Recent Events

  • 11 Jun 2018 Efficacy and adverse events data from a phase IIb/III trial in Migraine released by Allergan
  • 23 Apr 2018 Allergan completes a phase II/III trial for Migraine (Prevention) in USA (PO) (NCT02848326)
  • 14 Sep 2017 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top